Boston, MA, United States of America

Anand Minajigi

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Anand Minajigi in Gene Reactivation

Introduction

Anand Minajigi is a notable inventor based in Boston, MA, who has made significant contributions to the field of genetics. He holds two patents that focus on innovative methods for reactivating genes on the inactive X chromosome. His work is crucial in advancing our understanding of gene regulation and potential therapeutic applications.

Latest Patents

Minajigi's latest patents involve methods for reactivating genes on the inactive X chromosome. These methods include administering one or both of a DNA methyltransferase (DNMT) inhibitor and/or a topoisomerase inhibitor, such as etoposide and/or 5′-azacytidine (aza). Additionally, these methods may be combined with an inhibitor of XIST RNA and/or an Xist-interacting protein, which can include chromatin-modifying proteins, small molecules, or inhibitory nucleic acids like small inhibitory RNA (siRNAs) or antisense oligonucleotides (ASOs) that target XIST RNA and/or genes encoding Xist-interacting proteins.

Career Highlights

Anand Minajigi is affiliated with The General Hospital Corporation, where he continues to pursue his research and innovation in genetics. His work has the potential to impact various fields, including medicine and biotechnology.

Collaborations

Some of his notable coworkers include Jeannie T Lee and Lieselot Carrette, who contribute to the collaborative efforts in his research endeavors.

Conclusion

Anand Minajigi's innovative approaches to gene reactivation represent a significant advancement in genetic research. His contributions are paving the way for future developments in therapeutic strategies targeting gene regulation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…